ESMO WCGIC 2023 | Current and future trends in immunotherapy for MSI-H colorectal cancer

Kristen Ciombor, MD, MSCI, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the role of immune checkpoint inhibitors for high microsatellite instability (MSI-H) colorectal cancer. Immunotherapy has already been established as a treatment strategy in the refractory setting, and recent research suggests the use of PD-1 inhibitors in the first-line setting. Dr Ciombor additionally highlights immunotherapy as a promising treatment modality in locally advanced colorectal cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.